¶ Lewy Body Formation Pathway in Parkinson's Disease
Lewy bodies (LBs) are hallmark intracellular inclusions characteristic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). These proteinaceous aggregates primarily consist of alpha-synuclein (α-syn) along with numerous other proteins, lipids, and cellular components. Understanding Lewy body formation is crucial for elucidating PD pathogenesis and developing disease-modifying therapies.
¶ Lewy Body Biology
¶ Morphology and Classification
flowchart TD
A[Lewy Body Formation] --> B[Soluble α-Syn Monomers]
B --> C[α-Syn Misfolding]
C --> D[Oligomeric Intermediates]
D --> E[Protofibrils]
E --> F[Fibrillar Aggregates]
F --> G[Lewy Bodies]
G --> H[Classical LBs]
G --> I[Cortical LBs]
G --> J[Incidental LBs]
| Type |
Location |
Characteristics |
| Classical (Brainstem) |
Substantia nigra, locus coeruleus |
Dense core, halos, ubiquitin-positive |
| Cortical |
Cerebral cortex |
Diffuse, less organized |
| Transitional |
Limbic system |
Intermediate features |
- Core: Densely packed, 8-10 nm diameter fibrils
- Halo: Radiating fibrils, 80-200 nm wide
- Membranous organelles: Mitochondria, lysosomes, ER fragments
- Lipid membranes: Disrupted cellular membranes
Alpha-Synuclein
- Principal component (up to 95% of protein mass)
- Post-translational modifications: phosphorylation (Ser129), ubiquitination, nitration
- Conformations: monomeric, oligomeric, fibrillar
Associated Proteins
| Protein |
Role |
Significance |
| Ubiquitin |
Protein degradation tag |
Ubiquitinated in LBs |
| p62/SQSTM1 |
Selective autophagy receptor |
Autophagy-lysosome pathway |
| Parkin |
E3 ubiquitin ligase |
Genetic link to PD |
| Synphilin-1 |
α-Syn interacting protein |
Co-aggregation |
| Tubulin |
Cytoskeletal protein |
Fibril organization |
| Neurofilaments |
Cytoskeletal proteins |
Structural components |
- Phospholipids: From disrupted membranes
- Gangliosides: GM1, GM3 alterations
- Cholesterol: Altered metabolism
- Primary nucleation: Spontaneous α-syn monomer conversion
- Secondary nucleation: Fibril surface catalyzes new aggregates
- Oligomer formation: Toxic intermediate species
- Fibril elongation: Template-directed polymerization
- Maturation: Formation of Lewy bodies
flowchart LR
subgraph "Aggregation Triggers"
A[Genetic Mutations] --> D[Aggregation]
B[Oxidative Stress] --> D
C[Protein Clearance Defects] --> D
end
subgraph "Aggregation Process"
D --> E[Misfolding]
E --> F[Oligomerization]
F --> G[Fibrillization]
end
subgraph "Clearance Mechanisms"
H[Proteasome] -.-> D
I[Autophagy] -.-> D
J[ chaperones] -.-> D
end
SNCA Multiplications
- Gene duplication/triplication causes familial PD
- Dose-dependent disease severity
- Confirms α-syn as disease driver
Point Mutations
- A53T, A30P, E46K, H50Q, G51D
- Alter aggregation kinetics
- Enhance fibril formation
- Oxidative stress: ROS modify α-syn, promoting aggregation
- Metal ions: Iron, copper catalyze oxidation
- Pesticides: Rotenone, MPTP exposure
- Traumatic brain injury: Increases LB formation risk
The Braak staging hypothesis proposes that pathological α-syn spreads:
- Stage 1-2: Lower brainstem (dorsal motor nucleus)
- Stage 3-4: Midbrain (substantia nigra)
- Stage 5-6: Forebrain, cortex
- Synaptic transmission: α-syn release and uptake
- Tunneling nanotubes: Direct cell-to-cell transfer
- Extracellular vesicles: Exosome-mediated spread
- Inflammation: Microglial spread
¶ Lewy Bodies and Neurodegeneration
Loss of Function
- Impaired synaptic vesicle recycling
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Lysosomal dysfunction
Gain of Toxic Function
- Pore-like oligomers
- Mitochondrial permeabilization
- Calcium dysregulation
- Oxidative stress generation
- Brainstem LBs: Motor symptoms (tremor, bradykinesia)
- Limbic LBs: Mood, autonomic dysfunction
- Cortical LBs: Cognitive impairment, hallucinations
| Approach |
Mechanism |
Status |
| Small molecule inhibitors |
Prevent oligomerization |
Research |
| Anti-α-syn antibodies |
Clear aggregated protein |
Clinical trials |
| Gene therapy |
Reduce α-syn expression |
Preclinical |
| ** chaperones** |
Stabilize native state |
Investigational |
- Autophagy enhancers: Rapamycin, trehalose
- Proteasome activators: Research
- Immunotherapy: Active and passive vaccination
- Prasinezumab: Anti-α-syn antibody (Phase 2)
- Cinpanemab: Anti-α-syn antibody (Phase 2)
- APO-α-syn: Gene therapy approach
- Goedert M, Jakes R, Spillantini MG. The significance of Tau and alpha-synuclein inclusions in neurodegenerative diseases. Nat Rev Neurol. 2019;15(8):465-476.
- Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
- Lashuel HA, Overk CR, Oueslati A, et al. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38-48.
- Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat. 2014;8:159.
- Wong YC, Krainc D. Alpha-synuclein toxicity in neurodegeneration. Nat Med. 2017;23(1):1-13.
- Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013;79(6):1044-1066.
- Villar-Piqué A, da Silva FL, Ventura S, et al. Alpha-synuclein amyloids in Parkinson's disease. Prog Mol Biol Transl Sci. 2015;133:169-202.
- Cheng J, Liao Y, Dong H, et al. Immunotherapy targeting alpha-synuclein aggregation. Nat Rev Neurol. 2022;18(12):691-703.